Skip to main content
Signal8

Ocean Biomedical, Inc. (OCEA)

Ocean Biomedical, Inc. operates as a biopharmaceutical firm committed to identifying and advancing novel therapeutic solutions for various medical challenges, including cancer, fibrotic disorders, infectious illnesses, and inflammation. The company's pipeline includes the development of both mono-specific and bi-specific humanized monoclonal antibodies (mAbs). These candidates are specifically designed to target Chi3l1, offering potential treatments for non-small cell lung cancer and glioblastoma multiforme. Additionally, they are progressing a small molecule drug candidate aimed at Chit1, intended to address Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. Leveraging its proprietary WPDS platform, Ocean Biomedical is also developing three further product candidates. These encompass a promising malaria vaccine, a humanized mAb therapeutic for malaria that targets the Plasmodium falciparum glutamic-acid-rich protein (PfGARP), and a small molecule malaria therapeutic also designed to interact with PfGARP. Furthermore, a treatment candidate for hospitalized COVID-19 patients is also under development. The company, established in 2019, maintains its operations in Providence, Rhode Island.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Ocean Biomedical, Inc. logo

Ocean Biomedical, Inc.

OTC:OCEAHealthcare
$0.0001
Mkt Cap$23K
EV-
Float206.24M
O/S232.37M
VOL9K sh
$ Vol$1
RVOL0.12×
Inst Own0.0%
Net Cash/Sh-
EarningsDec 2 · in 2w
Dilution
Short interest (FINRA)
Not computed: short interest % needs a single float figure, and the float on record is a bound or estimate.
Oct 30 (18d)
65.4K
Oct 30 (18d)prev 65.4K– 0.0%
1.53
Oct 30 (18d)prev 1.00▲ 53.0%
Borrow (IBKR)

The cost to borrow OCEA shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.

IBKR borrow fee and availability is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually
Off-exchange & settlement
76.8%
Nov 16 (1d)prev 0.1%▲ 76.7 pts

Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.

53
Jul 23 (117d)
Price, short interest & fails to deliver
Short interest · today's share basis23 settlements
Latest short interest settlements (today's share basis)
DateShares short
Oct 30, 202665.4K sh
Oct 15, 202665.4K sh
Sep 30, 202665.4K sh
Sep 15, 202665.4K sh
Aug 31, 202665.4K sh

The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.

Off-exchange short volume
Nov 16
Latest sessions
DateReported short
Nov 16, 202676.8%
Nov 12, 20260.1%
Nov 6, 202619.8%
Nov 5, 2026100.0%
Nov 4, 20269.1%
65-session median 7.3%mean 21.2%range 0.0–100.0%

130 calendar days requested; 66 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.

Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.

Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.

ATS venues (dark pools)

FINRA's weekly alternative trading system (dark pool) volume for OCEA: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.

The ATS venue breakdown is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually

As of the Oct 30, 2026 FINRA settlement, 65,401 OCEA shares were sold short (1.53 days to cover).